Table 1 Baseline characteristics of hemodialysis participants with and without overt cardiovascular comorbidities (coronary artery disease or cerebrovascular disease).

From: The relationship of indoxyl sulfate and p-cresyl sulfate with target cardiovascular proteins in hemodialysis patients

 

With cardiovascular comorbidities (n = 79)

Without cardiovascular comorbidities (n = 254)

p value

Age (years)

62.3 (11.1)

58.4 (11.6)

0.008

Male

45 (57.0)

132 (52.0)

0.437

Hemodialysis duration (years)

6.5 (5.14)

6.8 (5.81)

0.747

Cause of ESRD

Hypertension

9 (11.4)

27 (10.6)

0.849

Diabetes mellitus

35 (44.3)

83 (32.7)

0.059

Glomerulonephritis

23 (29.1)

95 (37.4)

0.179

Othersa

12 (15.2)

49 (19.3)

0.410

Arteriovenous shunt

Arteriovenous fistula

65 (82.3)

226 (89.0)

0.117

Arteriovenous graft

14 (17.7)

28 (11.0)

0.117

Comorbidities

Diabetes mellitus

42 (53.2)

103 (40.6)

0.048

Hypertension

70 (88.6)

188 (74.0)

0.007

Dyslipidemia

40 (50.6)

88 (34.6)

0.011

Medications

Antiplatelets/Warfarin

53 (67.1)

42 (16.5)

< 0.001

Anti-hypertensive drugs

50 (64.1)

106 (41.9)

0.001

Diabetes treatment drugs

36 (46.2)

75 (29.6)

0.007

Laboratory data

Ionized calcium (mg/dL)

4.7 (0.4)

4.6 (0.5)

0.651

Phosphate (mg/dL)

4.7 (1.1)

4.7 (1.1)

0.975

High sensitivity C-reactive protein (mg/L)

3.7 (6.6)

1.9 (3.1)

0.001

Total (Kt/V)

1.6 (0.2)

1.6 (0.3)

0.860

Uremic toxins

Free form indoxyl sulfate (μg/mL)

1.9 (1.9)

1.9 (3.0)

0.984

Free form p-cresyl sulfate (μg/mL)

1.6 (2.0)

1.3 (1.7)

0.163

  1. aOther causes of end-stage renal disease include polycystic kidney disease, tumor, systemic lupus erythematosus, gout, interstitial nephritis.